Temat: castration - Katalog OPAC zbiorów

Skocz do pozycji: 1.

Tytuł:: Apalutamide as a new option for postponing metastatic disease in hormone -resistant patients with biochemical recurrence in prostate cancer
Autorzy:: Dąbek, Bartosz
Powiązania:: https://bibliotekanauki.pl/articles/22676825.pdf
Data publikacji:: 2023-04-04
Wydawca:: Medical Education
Tematy:: non-metastatic castration-resistant prostate cancer
apalutamide
Opis:: Treatment of non-metastatic castration-resistant prostate cancer is a radically new option for cancer patients. Novel anti-hormonal therapy not only improves metastasis free survival but overall survival times and positively impacts quality of life. This case shows how apalutamide lowered tPSA level and postponed metastatic disease.
Źródło:: OncoReview; 2023, 13, 1; 24-26
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Skocz do pozycji: 2.

Tytuł:: Prostate cancer in clinical practice. First experiences with apalutamide within the context of therapeutic program B.56
Autorzy:: Trzebiński, Krzysztof
Powiązania:: https://bibliotekanauki.pl/articles/22676841.pdf
Data publikacji:: 2023-04-01
Wydawca:: Medical Education
Tematy:: non-metastatic castration-resistant prostate cancer
apalutamide
androgen receptor inhibitor
Opis:: The article contains a case report of patient diagnosed with castration-resistant non-metastatic prostate cancer, treated with a novel androgen receptor inhibitor – apalutamide.
Źródło:: OncoReview; 2023, 13, 1; 27-30
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Skocz do pozycji: 3.

Tytuł:: Apalutamid for treatment of nonmetastatic castration-resistant prostate cancer - case study
Autorzy:: Sikora-Kupis, Bożena
Powiązania:: https://bibliotekanauki.pl/articles/22676707.pdf
Data publikacji:: 2023-03-31
Wydawca:: Medical Education
Tematy:: non-metastatic castration-resistant prostate cancer
nmCRPC
androgen receptor targeted agents
ARTA
apalutamide
darolutamide
enzalutamide
Opis:: A special form of prostate cancer is non-metastatic castration-resistant prostate cancer. Patients with this form have rising prostate-specific antigen and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. The phase III trials demonstrated apalutamide, darolutamide or enzalutamide to be associated with a significantly longer median metastasis-free survival. The featured description presents one case of man with non-metastatic castration-resistant prostate cancer who was treated with apalutamide.
Źródło:: OncoReview; 2023, 13, 1; 6-8
2450-6125
Pojawia się w:: OncoReview
Dostawca treści:: Biblioteka Nauki

Artykuł

Informacja